Accendra Health sees 3% YOY growth, embarks on ‘next chapter’

RICHMOND, Va. – Accendra Health reported revenue of $709 million for the fourth quarter ended Dec. 31, 2025.

For the full year 2025, it reported $2.8 billion, representing 3% growth vs. prior year. Results, unless otherwise noted, reflect the company’s Patient Direct business, said executives.

The company ended the fourth quarter with the completion of the sale of its Products & Healthcare Services (P&HS) business on Dec. 31, 2025, to Platinum Equity for $375 million, and began operating under the name Accendra Health.

“We are extremely excited to embark on the next chapter of our business as Accendra Health,” said Edward Pesicka, president and CEO. “The next several months will be a period of transition as we work towards completing the separation from Owens & Minor, thereby unlocking the strength of Accendra Health. As we look ahead, we are entering 2026 as a leaner, more nimble company that is well positioned to drive sustainable growth and long-term value creation.”

“In addition, as we move forward, we will be focused on improving the strength of our financial position through cost controls, improved cash flow generation, and balance sheet optimization,” said Pesicka. “In the years ahead, we look forward to showcasing Accendra’s continuation of higher quality of earnings, low working capital requirements, and more stable and consistent cash flow generation leading to greater value for all stakeholders.”

Full year 2025 continuing operations key highlights:

• Net revenue of $2.8 billion, representing 3% growth vs. prior year
• Operating cash flow of $154 million
• Successful completion of sale of Products & Healthcare Services business, Owens 2026 Continuing Operations Financial Outlook

The company provided financial guidance for 2026; summarized below:

• Revenue ranging between $2.55 billion and $2.65 billion
• Adjusted EBITDA ranging between $335 million to $355 million